rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Edesa Biotech, Inc. - Common Shares

EDSA · Nasdaq

Health CareBiotechnologyNot moving yet

EDSA stood above a rising 150-day average in 20 of the last 52 weekly readings, and has been out of that trend for the last 13 weeks. It is 58.7% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 13
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$466K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
32 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 20 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$252KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months8
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Pardeep NijhawanChief Executive Officerbought1,000at $6.6010 Mar 2026filed 10 Mar 2026
Pardeep NijhawanChief Executive Officerbought10,000at $3.905 Mar 2026filed 6 Mar 2026
Pardeep NijhawanChief Executive Officerbought10,000at $4.264 Mar 2026filed 5 Mar 2026
Pardeep NijhawanChief Executive Officerbought10,000at $3.633 Mar 2026filed 4 Mar 2026
Pardeep NijhawanChief Executive Officerbought2,000at $2.002 Mar 2026filed 3 Mar 2026
Pardeep NijhawanChief Executive Officerbought1,000at $2.282 Mar 2026filed 3 Mar 2026
Pardeep NijhawanChief Executive Officerbought30,000at $2.2227 Feb 2026filed 2 Mar 2026
Pardeep NijhawanChief Executive Officerbought20,571at $1.5826 Feb 2026filed 2 Mar 2026
Michael J. BrooksPresidentbought2,000at $1.5726 Feb 2026filed 11 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders32+6 on the quarter
New · exited11 · 5
Reported value$29.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Velan Capital Investment Management LPunchanged · filed 14 Aug 2026827,500$6.7M00.0%
Rubric Capital Management LPreduced · filed 14 Aug 2026669,500$5.4M-18,000−2.6%
PERCEPTIVE ADVISORS LLCunchanged · filed 14 Aug 2026563,239$4.6M00.0%
MILLENNIUM MANAGEMENT LLCnew · filed 14 Aug 2026561,751$4.6M+561,751
Stonepine Capital Management, LLCadded · filed 14 Aug 2026456,439$3.2M+426,439+1421.5%
Boxer Capital Management, LLCnew · filed 14 Aug 2026205,000$1.7M+205,000
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 202681,839$665K-4,127−4.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202680,879$658K+3,825+5.0%
JANE STREET GROUP, LLCreduced · filed 14 Aug 202672,465$589K-43,256−37.4%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202638,718$315K+272+0.7%
31 Dec 2023 – 30 Jun 2026
172431Dec 23Sep 24Mar 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Pardeep Nijhawan Company insiderChief Executive Officer · last 5 Oct 202619 · 0
Carlo Sistilli Company insiderDirector · last 27 May 20261 · 0
Charles Olson V Company insiderDirector · last 27 May 20260 · 0
Da David Liu Company insiderDirector · last 27 May 20260 · 0
Joan Chypyha Company insiderDirector · last 27 May 20260 · 0
Michael J. Brooks Company insiderPresident · last 27 May 202611 · 0
Patrick Marshall Company insiderDirector · last 27 May 20260 · 0
Peter J. Weiler Company insiderChief Financial Officer · last 27 May 20260 · 0
Sean Arthur MacDonald Company insiderDirector · last 27 May 20260 · 0
Stephen Lemieux Company insiderChief Financial Officer · last 4 Aug 20230 · 0
Frank R. Oakes Company insiderDirector · last 20 Jul 20230 · 4
Der Velden Peter Van Company insider10% owner · last 10 Jan 20230 · 2

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 30 Sep 2025-63.5%
Share count trendFY 2025 · to 12 Dec 202516.7%
Cash and equivalentsFY 2025 · to 30 Sep 2025$10.8M

Analyst forecasts

No analyst forecasts yet.